Hospital Acquired Pneumonia Drugs Market to Be Dominated by Biological Drugs, Phase III Drugs to Garner US $3.8 Billion
Hospital acquired infections can create several complications for patients. These infections, caused due to multidrug resistant organisms, drastically reduce the convalescence of a patient and is often accompanied with comorbidities.
View full press release